Research programme: immune suppression type 1 diabetes therapy - Celldex Therapeutics Inc

Drug Profile

Research programme: immune suppression type 1 diabetes therapy - Celldex Therapeutics Inc

Alternative Names: CDX-S03

Latest Information Update: 11 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Celldex Therapeutics Inc
  • Developer Celldex Therapeutics
  • Class
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Type 1 diabetes mellitus

Most Recent Events

  • 11 Nov 2016 Discontinued - Preclinical for Type-1 diabetes mellitus in USA (unspecified route) (Celldex Therapeutics pipeline) before November 2016
  • 14 Apr 2011 Preclinical development is ongoing in USA
  • 30 Sep 2008 AVANT Immunotherapeutics is now called Celldex Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top